Clinical Trial

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapsed/refractory CD19-positive B-cell hematologic malignancies and autoimmune hemolytic anemia. Interim analysis conducted when 2 patients complete primary endpoint measurement.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-09-25; most recent amendment 2026-07-16.
Trial Details
NCT Number NCT07205315
Lead Sponsor Grit Biotechnology
Collaborators: Zhengzhou Yihe Hospital, Institute of Hematology & Blood Diseases Hospital, China, Vivacta Biotechnology (Shanghai) Co., Ltd.
Conditions B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL), Autoimmune Hemolytic Anemia (AIHA)
Enrollment 28 participants
Start Date 2025-09-26
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-20